source
- Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancerMerck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
- Celldex drops eczema antibody barzolvolimab after Phase 2 failureCelldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…